MedWatch

Finance analyst: Novo's sales from obesity drugs may grow earlier than anticipated

Novo Nordisk may see accelerated sales of obesity drugs sooner than expected, thinks Danish bank analyst, who sees great potential in upcoming new data for semaglutide as an obesity treatment.

Photo: Novo Nordisk / PR

Preliminary data from a crucial trial concerning a Novo Nordisk obesity drug may accelerate sales in 2023, according to Danish newspaper Børsen in reference to an analysis from Danish bank and financial analyst Nordea.

The growth escalation in Novo Nordisk's obesity drug sales may actually become a factor some years earlier than what both Novo Nordisk and the stock market have expected.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Sanofi reduces US insulin prices for the uninsured

While bills to introduce a price cap on insulin are being discussed in the US Senate, Sanofi has beaten them to the punch and reduced the price of insulin products for US diabetes patients without insurance.

Further reading

Related articles

Latest news

See all jobs